BioSpace News Archive

Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration has approved Vabysmo® for the treatment of macular edema following retinal vein occlusion.

Specialty Care grew 13.5% driven by Dupixent® and ALTUVIIIO® more than offsetting the impact of Aubagio® generic competition in the U.S.

Opthea Limited announced that the company’s Chief Executive Officer, Dr. Megan Baldwin, will transition to Founder and Chief Innovation Officer, reflective of the company’s strategy to advance its US and global presence and commercialization strategy for sozinibercept.

Prime Medicine, Inc. reported new preclinical data demonstrating the ability of liver-targeted Prime Editors to efficiently and precisely correct one of the most prevalent disease-causing mutations of glycogen storage disease 1b in non-human primates and mouse models.

ImmunoGen, Inc. announced that the European Medicines Agency has accepted the Marketing Authorization Application for mirvetuximab soravtansine for the treatment of patients with folate receptor alpha -positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the publication of a peer-reviewed paper in Nature Communications showing the ability of an alpha-synuclein (a-syn) positron emission tomography (PET) tracer to identify patients with multiple system atrophy (MSA).

G1 Therapeutics, Inc. announced the presentation of four posters that provide new-real world evidence indicating that trilaciclib administered prior to platinum-based chemotherapy in patients with extensive-stage small cell lung cancer lowers the rate of hospitalization and cytopenia events and may improve survival.

Microbix Biosystems Inc. announces that its quality assessment products are supporting a testing program for Human Papilloma Virus using molecular diagnostic technology at Dublin’s The Coombe Hospital, in the Republic of Ireland, an EU member-state.

Monte Rosa Therapeutics today announced that management will participate in the following investor conferences.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present two abstracts on oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI).